Paclitaxel promotes lung cancer cell apoptosis via MEG3-P53 pathway activation

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Paclitaxel (PTX) is a key chemotherapy for advanced non-small cell lung cancer (NSCLC).
• Maternally expressed gene 3 (MEG3), a long non-coding RNA, functions as a tumor suppressor.
• Understanding PTX's molecular mechanisms in NSCLC is crucial for optimizing treatment.

Purpose of the Study:

• To investigate the impact of PTX on MEG3 expression in lung cancer cells.
• To elucidate the anti-tumorigenic mechanisms of PTX involving MEG3.
• To explore the interplay between MEG3 and P53 in PTX-induced apoptosis.

Main Methods:

• Cell proliferation assessed by MTT assays.
• MEG3 and P53 expression analyzed via qRT-PCR and Western blotting.
• Apoptosis and reactive oxygen species (ROS) detected by flow cytometry and DCFH-DA staining, respectively.
• Gene manipulation using siRNA and plasmid transfection to alter MEG3 levels.

Main Results:

• PTX significantly inhibited NSCLC cell proliferation and upregulated MEG3 and P53 expression.
• Downregulation of MEG3 diminished PTX's cytotoxic effects.
• Upregulation of MEG3 induced apoptosis and enhanced P53 expression.
• P53 inhibition did not affect upstream MEG3 levels, indicating a unidirectional pathway.

Conclusions:

• The MEG3-P53 axis is integral to PTX-induced apoptosis in A549 lung cancer cells.
• MEG3 acts as a mediator of PTX's anti-cancer effects.
• Targeting the MEG3-P53 pathway may represent a novel therapeutic strategy for NSCLC.